FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2608213513> ?p ?o ?g. }

• W2608213513 endingPage "364" @default.
• W2608213513 startingPage "349" @default.
• W2608213513 abstract "Co-delivery of multiple drugs with complementary anticancer mechanisms by nano-carriers offers an effective strategy to treat cancer. The combination of drugs with pro-apoptotic and anti-angiogenic activities is potentially effective in treating human hepatocellular carcinoma (HCC). Herein, we developed a co-delivery system for doxorubicin (Dox), a pro-apoptotic drug, and curcumin (Cur), a potent drug for antiangiogenesis, in pH-sensitive nanoparticles (NPs) constituted with amphiphilic poly(β-amino ester) copolymer. Dox & Cur co-loaded NPs ((D + C)/NPs) were prepared with optimized drug ratio, showing low polydispersity, high encapsulation efficiency, and enhanced release in the acidic environment of cancer cells. Furthermore, enhanced cellular internalization of cargoes delivered from (D + C)/NPs were observed in human liver cancer SMMC 7721 cells and human umbilical vein endothelial cells (HUVECs) compared to the use of free drugs. The (D + C)/NPs induced a high rate of apoptosis in SMMC 7721 cells through decreased mitochondrial membrane potential. Additionally, (D + C)/NPs exhibited stronger anti-angiogenic effects including inhibition of HUVEC proliferation, migration, invasion, and tube formation mediated VEGF pathway modulation in vitro and in vivo. Taken together, encapsulation of the pro-apoptotic drug Dox and antiangiogenic agent Cur in pH-sensitive NPs provides a promising strategy to effectively inhibit HCC progression in a synergistic manner. The combination of multiple drugs has been demonstrated to be more effective than single treatment. However, the different physicochemical and pharmacokinetic profiles of each drug render optimal delivery challenging. In view of the great delivery advantage of nanocarriers to unify the multiple drugs in vivo, stimulus-responsive nano-carriers are more crucial to increase efficacy and reduce toxicity from off-target exposure. Therefore, herein the pH-sensitive nanoparticles, composed by d-α-tocopheryl polyethylene glycol 1000-block-poly (β-amino ester) (TPGS-PAE) polymers, have been fabricated for doxorubicin (Dox) and curcumin (Cur) co-delivery, which exhibited diverse anticancer approaches, i.e. pro-apoptosis and antiangiogenesis. The precise intracellular target site and effective drug combination concentration result in the enhanced antitumor efficiency and the reduced systematic toxicity of Dox. The co-encapsulation of the pro-apoptotic drug and antiangiogenic agent in pH-sensitive NPs provides a promising strategy to effectively inhibit malignant neoplasm progression in a synergistic manner." @default.
• W2608213513 created "2017-05-05" @default.
• W2608213513 creator A5032823744 @default.
• W2608213513 creator A5035375969 @default.
• W2608213513 creator A5048003025 @default.
• W2608213513 creator A5049692788 @default.
• W2608213513 creator A5053935265 @default.
• W2608213513 creator A5063083521 @default.
• W2608213513 creator A5064786959 @default.
• W2608213513 creator A5074757942 @default.
• W2608213513 creator A5079425473 @default.
• W2608213513 date "2017-08-01" @default.
• W2608213513 modified "2023-10-15" @default.
• W2608213513 title "pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities" @default.
• W2608213513 cites W1186835836 @default.
• W2608213513 cites W1963526834 @default.
• W2608213513 cites W1963722513 @default.
• W2608213513 cites W1964278583 @default.
• W2608213513 cites W1967378899 @default.
• W2608213513 cites W1981072770 @default.
• W2608213513 cites W1981131114 @default.
• W2608213513 cites W1990642150 @default.
• W2608213513 cites W2000691433 @default.
• W2608213513 cites W2001612306 @default.
• W2608213513 cites W2002090994 @default.
• W2608213513 cites W2005475049 @default.
• W2608213513 cites W2006250811 @default.
• W2608213513 cites W2007807680 @default.
• W2608213513 cites W2013951470 @default.
• W2608213513 cites W2020797655 @default.
• W2608213513 cites W2026787525 @default.
• W2608213513 cites W2027354237 @default.
• W2608213513 cites W2027820615 @default.
• W2608213513 cites W2044210828 @default.
• W2608213513 cites W2056527566 @default.
• W2608213513 cites W2056812738 @default.
• W2608213513 cites W2057256078 @default.
• W2608213513 cites W2059860479 @default.
• W2608213513 cites W2063250955 @default.
• W2608213513 cites W2067337823 @default.
• W2608213513 cites W2069428454 @default.
• W2608213513 cites W2076946660 @default.
• W2608213513 cites W2084590325 @default.
• W2608213513 cites W2106530175 @default.
• W2608213513 cites W2109408781 @default.
• W2608213513 cites W2111281808 @default.
• W2608213513 cites W2124732632 @default.
• W2608213513 cites W2126036312 @default.
• W2608213513 cites W2128168622 @default.
• W2608213513 cites W2128249174 @default.
• W2608213513 cites W2137794530 @default.
• W2608213513 cites W2140486739 @default.
• W2608213513 cites W2152035318 @default.
• W2608213513 cites W2157122000 @default.
• W2608213513 cites W2163382189 @default.
• W2608213513 cites W2300626327 @default.
• W2608213513 cites W2404933325 @default.
• W2608213513 doi "https://doi.org/10.1016/j.actbio.2017.04.029" @default.
• W2608213513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28455219" @default.
• W2608213513 hasPublicationYear "2017" @default.
• W2608213513 type Work @default.
• W2608213513 sameAs 2608213513 @default.
• W2608213513 citedByCount "143" @default.
• W2608213513 countsByYear W26082135132017 @default.
• W2608213513 countsByYear W26082135132018 @default.
• W2608213513 countsByYear W26082135132019 @default.
• W2608213513 countsByYear W26082135132020 @default.
• W2608213513 countsByYear W26082135132021 @default.
• W2608213513 countsByYear W26082135132022 @default.
• W2608213513 countsByYear W26082135132023 @default.
• W2608213513 crossrefType "journal-article" @default.
• W2608213513 hasAuthorship W2608213513A5032823744 @default.
• W2608213513 hasAuthorship W2608213513A5035375969 @default.
• W2608213513 hasAuthorship W2608213513A5048003025 @default.
• W2608213513 hasAuthorship W2608213513A5049692788 @default.
• W2608213513 hasAuthorship W2608213513A5053935265 @default.
• W2608213513 hasAuthorship W2608213513A5063083521 @default.
• W2608213513 hasAuthorship W2608213513A5064786959 @default.
• W2608213513 hasAuthorship W2608213513A5074757942 @default.
• W2608213513 hasAuthorship W2608213513A5079425473 @default.
• W2608213513 hasConcept C121608353 @default.
• W2608213513 hasConcept C126322002 @default.
• W2608213513 hasConcept C13245373 @default.
• W2608213513 hasConcept C141071460 @default.
• W2608213513 hasConcept C150903083 @default.
• W2608213513 hasConcept C155672457 @default.
• W2608213513 hasConcept C171250308 @default.
• W2608213513 hasConcept C18150654 @default.
• W2608213513 hasConcept C185592680 @default.
• W2608213513 hasConcept C190283241 @default.
• W2608213513 hasConcept C192562407 @default.
• W2608213513 hasConcept C202751555 @default.
• W2608213513 hasConcept C204399865 @default.
• W2608213513 hasConcept C207001950 @default.
• W2608213513 hasConcept C2776694085 @default.
• W2608213513 hasConcept C2777411675 @default.
• W2608213513 hasConcept C2778250585 @default.
• W2608213513 hasConcept C2779820397 @default.

• next